Yamashita, Yugo http://orcid.org/0000-0003-2583-1321
Morimoto, Takeshi
Klok, Frederikus A.
Barco, Stefano
Nishimoto, Yuji
Kato, Takao
Ono, Koh
Kimura, Takeshi
,
Funding for this research was provided by:
Research Institute for Production Development
Mitsubishi Tanabe Pharma Corporation
Article History
Accepted: 9 May 2022
First Online: 17 June 2022
Declarations
:
: Dr. Yamashita received lecture fees from Daiichi-Sankyo, Bristol-Myers Squibb, Pfizer, and Bayer Healthcare. Dr Morimoto reports lecturer's fees from Bristol-Myers Squibb, Daiichi Sankyo, Japan Lifeline, Kowa, Kyocera, Novartis, and Toray; manuscript fees from Bristol-Myers Squibb and Kowa; advisory board for Sanofi. Dr. Klok reports research grants from Bayer, Bristol-Myers Squibb, Boehringer-Ingelheim, MSD, Daiichi-Sankyo, Actelion, the Dutch thrombosis association, The Netherlands Organization for Health Research and Development and the Dutch Heart foundation, all outside the current work. Dr. Nishimoto received lecture fees from Daiichi-Sankyo, Bristol-Myers Squibb, Pfizer, and Bayer Healthcare. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.
: All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. For the COMMAND VTE Registry of retrospective study formal consent is not required.